Cellenkos scores FDA orphan drug designation for CK0804 in rare blood cancer
Receiving Orphan Drug Designation is an important milestone in the clinical development of CK0804 for myelofibrosis
Receiving Orphan Drug Designation is an important milestone in the clinical development of CK0804 for myelofibrosis
The therapy was well tolerated through Week 24, with a safety profile consistent with Alumis’ Phase 2 data
Blood tests measuring biomarkers such as p-tau217 are emerging as accurate, accessible alternatives
The MAGiC catheter is designed for robotically-navigated cardiac ablation procedures
REDEMPLO is the first and only Health Canada-approved siRNA therapy for FCS
It is currently the only vaccine authorized by the Drug Controller General of India (DCGI) for active immunization against HEV in adults aged 18 to 65
Sovaaka offers a deeply personalised diagnostics-led wellness experience that goes beyond routine health checks
The work will leverage ProBioGen’s CHO.RiGHT expression platform, powered by its proprietary DirectedLuck transposase technology, alongside PsiBot smart automation
Currently approved for patients eight and older, Tzield could now be used to delay the onset of stage 3 type 1 diabetes (T1D) in children diagnosed with stage 2 T1D
Mepolizumab is the first and only monthly biologic in China tested for COPD patients with blood eosinophil counts (BEC) as low as 150 cells/µL
Subscribe To Our Newsletter & Stay Updated